Citizens Financial Group Inc. RI Acquires 77,780 Shares of Pfizer Inc. (NYSE:PFE)

Citizens Financial Group Inc. RI increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 63.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 200,310 shares of the biopharmaceutical company’s stock after buying an additional 77,780 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $5,605,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer during the 2nd quarter worth $29,000. Creekmur Asset Management LLC acquired a new position in Pfizer in the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the second quarter valued at about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $30.07 on Tuesday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.12. The company has a fifty day moving average of $29.26 and a 200-day moving average of $28.15. The firm has a market capitalization of $170.40 billion, a P/E ratio of -501.08, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.59%. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.